PMV Pharma's Rezatapopt Shows Promise in First-in-Human Study for TP53 Y220C-Mutated Solid Tumors
核心洞察
PMV Pharmaceuticals published first-in-human Phase 1 results for rezatapopt in the New England Journal of Medicine, demonstrating selective p53 reactivation in 77 heavily pretreated patients with TP53 (搜索) Y220C-mutated solid tumors (搜索).
The study established proof-of-concept for p53 reactivation therapy, with objective responses observed across multiple tumor types and all responding patients having TP53 (搜索) Y220C mutations and KRAS (搜索) wild-type status.
Updated Phase 2 data showed an overall response rate of 34% across all cohorts and 46% in ovarian cancer (搜索) patients, with median duration of response reaching 8.0 months in the ovarian cancer cohort.
PMV Pharmaceuticals announced the publication of first-in-human Phase 1 results for rezatapopt in the New England Journal of Medicine, marking a significant milestone for the first-in-class p53 reactivator targeting TP53 (搜索) Y220C-mutated solid tumors (搜索). The study demonstrated selective reactivation of mutant p53 in 77 heavily pretreated patients with advanced solid tumors (搜索), establishing proof-of-concept for this novel therapeutic approach.
Phase 1 Study Design and Patient Population
The Phase 1 portion of the ongoing PYNNACLE clinical trial enrolled 77 heavily pretreated patients with advanced solid tumors (搜索) harboring a TP53 (搜索) Y220C mutation. Patients received oral rezatapopt across dose-escalation cohorts to determine the maximum tolerated dose and recommended Phase 2 dose (RP2D). The study also characterized safety, pharmacokinetics, and biomarker effects of the treatment.
Rezatapopt was generally well tolerated, with dose-limiting toxicities occurring infrequently, supporting the selection of the RP2D. Objective responses were observed across multiple tumor types, with clinical activity and biomarker data consistent with selective binding to the Y220C pocket and restoration of wild-type p53 tumor suppressor function.
Clinical Efficacy Results
All responding patients in the Phase 1 study had a TP53 (搜索) Y220C mutation and were KRAS (搜索) wild-type, demonstrating the selective nature of rezatapopt's mechanism of action. The study highlighted antitumor activity across multiple solid tumor types, providing crucial proof-of-concept data for p53 reactivation therapy.
Updated interim results from the Phase 2 pivotal portion of the PYNNACLE study, presented in October 2025, showed confirmed responses in patients with TP53 (搜索) Y220C-mutated and KRAS (搜索) wild-type tumors across eight tumor types, including ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder cancers, and ampullary carcinoma (搜索).
As of the September 4, 2025 data cutoff, the overall response rate (ORR) across all cohorts was 34% (35/103 patients), with an ORR of 46% (22/48 patients) in ovarian cancer (搜索) per investigator assessment according to RECIST version 1.1. Across all cohorts, the median time to response was 1.3 months, and the median duration of response was 7.6 months. In the ovarian cancer cohort specifically, the median time to response was 1.3 months and the median duration of response was 8.0 months.
Regulatory Status and Development Timeline
The U.S. Food and Drug Administration has granted Fast Track designation to rezatapopt for the treatment of patients with locally advanced or metastatic solid tumors (搜索) with a p53 Y220C mutation. This designation recognizes the significant unmet medical need in this patient population and the potential for rezatapopt to address it.
"Publication of the rezatapopt Phase 1 results in the New England Journal of Medicine underscores the emerging clinical impact of reactivating p53 in patients whose cancers are driven by a TP53 (搜索) Y220C mutation," said Deepika Jalota, Pharm.D., Chief Development Officer of PMV Pharma (搜索). "These peer-reviewed findings further validate our scientific approach, support our registrational Phase 2 strategy and our plan to submit a New Drug Application in platinum-resistant/refractory ovarian cancer (搜索) in the first quarter of 2027."
Mechanism of Action and Clinical Significance
Rezatapopt (PC14586) is designed as a first-in-class, small molecule p53 reactivator that selectively binds to the pocket in the p53 Y220C mutant protein, restoring wild-type tumor-suppressor function. This approach represents a novel therapeutic strategy for cancers driven by specific p53 mutations.
TP53 (搜索) mutations are found in approximately half of all cancers, making p53 a critical target for cancer therapy. PMV Pharma (搜索)'s co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979, providing the company with unique biological understanding combined with pharmaceutical development focus.
Ongoing Clinical Development
The Phase 2 portion of the PYNNACLE study is a registrational, single-arm, expansion basket clinical trial comprising five cohorts: ovarian, lung, breast, and endometrial cancers, and other solid tumors (搜索). The primary objective is evaluating the efficacy of rezatapopt at the RP2D in patients with TP53 (搜索) Y220C and KRAS (搜索) wild-type advanced solid tumors (搜索).
The company remains focused on advancing rezatapopt as a potential first-in-class therapy for ovarian cancer (搜索) patients harboring a TP53 (搜索) Y220C mutation, addressing an area of high unmet medical need in platinum-resistant/refractory ovarian cancer.